Fate Therapeutics, Inc. (NASDAQ:FATE) General Counsel Cindy Tahl sold 8,091 shares of Fate Therapeutics stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.85, for a total value of $31,150.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Fate Therapeutics, Inc. (NASDAQ:FATE) traded up 0.49% during mid-day trading on Tuesday, reaching $4.08. The company’s stock had a trading volume of 114,863 shares. The stock’s 50 day moving average is $4.06 and its 200 day moving average is $3.67. Fate Therapeutics, Inc. has a one year low of $1.80 and a one year high of $5.68. The firm’s market cap is $168.97 million.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. Fate Therapeutics had a negative return on equity of 67.01% and a negative net margin of 887.68%. On average, analysts anticipate that Fate Therapeutics, Inc. will post ($0.97) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/17/cindy-tahl-sells-8091-shares-of-fate-therapeutics-inc-fate-stock.html.

A number of equities analysts have recently commented on the company. Zacks Investment Research cut Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 6th. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Thursday, October 12th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $6.79.

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Fate Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock worth $4,096,000 after purchasing an additional 108,602 shares during the last quarter. Morgan Stanley grew its holdings in shares of Fate Therapeutics by 9.8% during the first quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after purchasing an additional 54,615 shares during the last quarter. State Street Corp purchased a new position in shares of Fate Therapeutics during the second quarter worth about $1,437,000. Northern Trust Corp grew its holdings in shares of Fate Therapeutics by 968.7% during the second quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 333,753 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Fate Therapeutics by 40.9% during the first quarter. Renaissance Technologies LLC now owns 295,700 shares of the biopharmaceutical company’s stock worth $1,345,000 after purchasing an additional 85,800 shares during the last quarter. 64.27% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.